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Potential mechanisms for the effects of Far-infrared on the cardiovascular system: a 
systematic review 
Richard Shemilt, Hala Bagabir, Chim Lang, and Faisel Khan 
Division of Molecular and Clinical Medicine, University of Dundee
Summary:  
Far-infrared (FIR) is a form of thermal radiation, which may have beneficial effects on cardiovascular health. 
Clinical studies suggest that FIR irradiation may have therapeutic effects in heart failure, myocardial ischaemia 
and may improve flow and survival of arteriovenous fistula. Animal studies have suggested a wide range of 
potential mechanisms involving endothelial nitric oxide synthase and nitric oxide bioavailability, oxidative stress, 
heat shock proteins and endothelial precursor cells. However, the exact cellular and molecular mechanism of 
FIR on the cardiovascular system remains elusive. The purpose of this review is to discuss the current literature, 
focusing on mechanistic studies involving the cardiovascular system, and with a view to highlighting areas for 
future investigation. 
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Introduction 
Far infrared (FIR) is an invisible form of electromagnetic solar energy with a wavelength ranging between 3.0-
1000 μm [1]. The therapeutic uses of FIR can be divided into two main categories, which have been investigated 
in studies contributing to a growing body of research. The first is FIR dry sauna therapy (Figure 1), which is also 
known as ‘Waon’ therapy meaning ‘soothing warmth’ in Japanese. This involves irradiating the entire body with 
FIR in a sauna (Figure 1) at 60 °C for 15 minutes, followed by a further 30 minutes covered in blankets to cause 
an increase in core body temperature of around 1 °C. [2, 3]. Localised FIR therapy is the other form, which 
typically consists of a device with ceramic plates which emit FIR irradiation when electrically 
heated. The emitter is usually placed 20–30 cm above the skin surface and causes a steady increase in skin 
temperature peaking at 38–39 °C. [4]. Over the past two decades, research has consistently suggested that FIR 
may have beneficial effects on a number of aspects of health, ranging from increasing the rate of wound healing 
to reducing breathlessness in heart failure [2, 5]. One of the major benefits appears to be in relation to endothelial 
function, the principal regulator of the cardiovascular system [6]. It is therefore thought that FIR may represent a 
potential novel, non-invasive therapeutic modality for a wide range of diseases, which have pathophysiological 
roots in the cardiovascular system. Most significantly in relation to clinical practice, human studies have 
suggested that FIR may improve patency and flow in arteriovenous fistulae (AVF) of dialysis patients and reduce 
symptoms of congestive heart failure [2, 7]. However, the future of FIR as a potential treatment depends on an 
improved understanding of a biological mechanism for its effects; something that has not yet been achieved. A 
number of potential mechanisms have been investigated, but none have fully explained the effects of FIR. An 
improved understanding of the mechanisms underpinning the apparent beneficial effects of FIR, is important to 
ensure that this novel, non-invasive therapy is used to maximal effect to augment current pharmacological 
approaches to cardiovascular disease. In this review, the current literature on FIR is summarised with a focus on 
effects on the cardiovascular system and cardiovascular disease, and on possible molecular mechanisms that 
have been identified to date. The methodology of the literature search is provided as a supplement (ESM 1). 
FIR radiation 
There is some debate surrounding the subdivision of the infrared spectrum by wavelength, which makes 
interpreting FIR studies challenging. The International Commission on Illumination describes FIR or IR-C as the 
wavelength between 3.0–1000 μm, whilst the alternative ISO20473 classification describes FIR as 50–1000 μm 
[1]. Of the studies included in this review, only a minority state the actual wavelength of irradiation produced by 
the FIR emitting device [7–12]. Most of the studies use a localised FIR device which produces irradiation in the 
range of 3–25 μm, with a peak at 5–6 μm. Whilst many of the devices used in these studies produce what would 
be considered mid-infrared under the ISO 20473 classification, they all meet the CIE definition of IR-C or FIR. It 
must be considered that the lack of exact wavelengths provided by many studies, particularly those using FIR 
sauna therapy makes interpretation of the results difficult. However, new units are currently being marketed which 
produce irradiation at wavelengths 8–14 μm and this information should be included in future studies. 
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Figure 1 (A) Far Infra-Red (FIR) ray device. (B) FIR suna. 
 
Haemodynamic effects of FIR in clinical studies 
The clinical effects of FIR have been examined in various clinical studies (Table I), including patients with heart 
failure, cardiovascular risk factors, ischaemic heart disease and peripheral arterial disease (PAD) [3, 13–22]. The 
majority of these are small studies examining a range of different clinical and physiological parameters and using 
a variety of methodologies. For example, many of the studies are randomised with a control group, but several 
lack a control, and all lack blinding of allocations to the subjects and investigators. Despite these flaws, there are 
findings suggesting a clinical benefit of FIR and some suggestion of potential mechanisms for these effects. Heart 
failure is the most well-researched condition with studies suggesting that both whole-body and localised FIR 
irradiation can improve shortness of breath and symptoms of heart failure, as well as improve endothelial function, 
reduce blood pressure and reduce plasma natriuretic peptides [3, 13, 17– 19, 22]. The clinical benefits of FIR 
appear to be partly due to haemodynamic effects, including causing vasodilatation which results in reduced 
afterload and strain on the heart. This may also increase shear stress resulting in increased nitric oxide production 
by the endothelium, which is discussed later in this review. The heating effect of FIR results in vasodilatation 
acutely, but several of the human studies have sought to reduce the impact of this acute effect by taking final 
measurements the day after completing the course of FIR [3, 15, 18]. These studies still reported significant 
improvements in symptoms of peripheral arterial disease and left ventricular ejection fraction (LVEF) in heart 
failure. This goes some way to addressing the question of whether FIR has an additional effect to that of simple 
heating, as a delayed effect would suggest this, though studies exploring the longer-term effects and controlling 
for temperature are required. Another well-researched area which is less directly relevant to the cardiovascular 
system and beyond the scope of this review, is in relation to AVF survival and patency in haemodialysis patients. 
One study was included which suggested a mechanism relating to the induction of heme oxygenase-1 (HO-1) 
and is discussed in detail under the section on oxidative stress. As cardiovascular disease is highly prevalent in 
patients with chronic kidney disease (CKD), future studies in dialysis patients could seek to investigate effects of 
FIR on wider cardiovascular function, as well as to the localised AVF site [23]. Although, the majority of human 
studies have been in patients with heart failure, benefits of FIR have also been reported in patients with PAD, 
cardiac ischaemia and patients with cardiovascular risk factors [14–16, 20]. Patients in all of these categories 
stand to benefit from the haemodynamic effects of FIR, which appear to include lowering blood pressure and 
increasing cardiac output. The strength of conclusions that can be drawn from current human studies is fairly low 
as many are small trials of carefully selected patients, which lack adequate controls, randomisation and blinding. 
Despite this, there are findings which justify larger scale clinical trials to establish the true effects and clinical 
benefits of FIR in patients with cardiovascular disease. 
 
Potential Mechanisms of FIR on the Cardiovascular System 
Thus far, it has been challenging to clearly delineate the mechanism of FIR on the cardiovascular system because 
of the diverse range of potential mechanisms reported in various animal and cellular models, as well as in some 
human studies (Figure 2). FIR may exert its effects through a range of mechanisms contributing to an overall 
beneficial effect on the cardiovascular system. It is also possible that current studies are yet to clearly identify 
which, if any of these potential mechanisms plays the most important role. In this review, we have grouped the 
current evidence into four broad categories to highlight some of the most important potential mechanisms 
identified to date. These are 1) Up-regulation of endothelial nitric oxide synthase (eNOS) and increase in nitric 
oxide (NO) bioavailability; 2) Improvement in redox status and reduction in oxidative stress; 3) Effects on 
angiogenesis and endothelial precursor cells and 4) Inflammation and thrombogenesis 
 
Upregulation of endothelial nitric oxide synthase (eNOS) and increased nitric oxide (NO) 
bioavailability 
The endothelium, the innermost layer of the blood vessel, is considered the central regulator of vascular health 
[6]. The endothelium inherently produces paracrine factors to maintain vascular health. NO is one of these 
essential factors that regulates vascular tone along with other important functions such as inhibition of platelet 
aggregation and vascular smooth muscle proliferation which are vital to cardiovascular health [24]. NO is 
produced in endothelial cells by the enzyme eNOS [25, 26]. FIR is thought to increase eNOS expression indirectly 
through changes in laminar shear stress. FIR causes vasodilation, which reduces peripheral vascular resistance 
and afterload. This increases cardiac output and increases peripheral blood flow [27], resulting in an increase in 
shear stress, which is one of the most important stimuli for eNOS [25] expression. This secondary effect of 
increasing eNOS expression through increased shear stress appears to be partly due to a temperature effect, as 
FIR increases skin temperature, a known stimulus for vasodilation. However, studies have shown that the 
beneficial effects of FIR on endothelial function persist beyond this temporary rise in skin temperature [3, 18]. 
This suggests further mechanisms for a beneficial primary effect of FIR on the vasculature. There is evidence 
from animal studies (Table II) to suggest that FIR irradiation may cause induction of eNOS directly, which leads 
to increased NO bioavailability and improves endothelial function. Different experimental studies have 
established the increase in expression of eNOS in heart and large vessel arterial tissue following FIR irradiation 
in mice with hindlimb ischaemia, healthy and cardiomyopathic hamsters, and hypertensive rats [28–31]. This 
increase in NO bioavailability appears to contribute to improvements in the response to ischaemic states induced 
to mimic human coronary and peripheral vascular disease. Sobajima et al. found that FIR sauna therapy partially 
reduced cardiac remodeling after induced myocardial infarction (MI) in rats, while Miyauchi et al. showed 
improved perfusion and neovascularization in mice with hindlimb ischaemia [32, 33]. In this case, there was 
upregulation of heat shock protein (HSP) 90, phosphorylated Akt/protein kinase B (PKB) and phosphorylated 
eNOS in arterial endothelial cells within sections of ischaemic muscle. The increase in angiogenesis caused by 
FIR irradiation was reduced by the application of an HSP90 inhibitor, suggesting this protein is integral to the 
mechanism. HSP90, a chaperone protein, is a part of the family of heat shock proteins, which is produced in 
response to stressful conditions [34, 35] and forms a complex with Akt/PKB resulting in phosphorylation of eNOS, 
increasing NO production and improving endothelial function [36]. Studies examining cellular models (Table III) 
have shown similar effects of FIR on eNOS and provide further mechanistic information about how FIR may 
mediate NO production. It has been found that eNOS phosphorylation and NO production are both increased in 
human umbilical vein endothelial cells (HUVECs) when exposed to FIR [8]. Hsu and colleagues also showed that 
FIR inhibited proliferation of HUVECs induced by vascular endothelial growth factor (VEGF), with this effect 
peaking 30 minutes into FIR irradiation [8]. The authors claimed that heating the cells to the same extent, without 
applying FIR did not inhibit proliferation, although it is unclear how this heating was done without the absorption 
of any infrared radiation. Nitrotyrosine formation increased in HUVECs treated with FIR and VEGF. This suggests 
an FIR-specific effect independent of temperature, involving VEGF-induced production of superoxide anions 
which combine with NO to inhibit vascular proliferation. The beneficial effect of FIR on PKB/Akt and eNOS 
phosphorylation was abolished when phosphoinositide 3-kinase (PI3K) was inhibited, suggesting that this 
enzyme which is also involved in cell growth and proliferation [37], mediates FIR’s modulatory effect on eNOS. 
FIR exposure induced the nuclear translocation of promyelocytic leukaemia zinc finger protein (PLZF), which 
encodes proteins regulating myelopoiesis. Again, this effect was not replicated by heating without FIR. In 
conclusion, it appeared that FIR induced the nuclear translocation of PLZF, which increased PI3K expression. 
This in turn activated PKB/Akt to phosphorylate eNOS, resulting in the beneficial end-result of increased NO 
production. Up-regulation of HSP90 and Akt/PKB could be an important target in treating human cardiovascular 
disease for a number of reasons. It results in increased phosphorylation of eNOS and NO production, which 
maintains healthy vasculature and guards against endothelial dysfunction [38]. Significantly, Akt/PKB 
dysregulation has also been shown to promote coronary atherosclerosis through an increase in expression of 
pro-inflammatory genes, and to reduce postischaemic inflammatory and proliferative change in mouse models 
[39, 40]. Although predominantly animal models have been investigated, the evidence suggests a potential role 
of the Akt/PKB pathway in maintaining healthy vasculature. Based on current limited studies it is difficult to 
determine the importance of this mechanism in the apparent effects of FIR. If this mechanism was replicated in 
further animal studies and even a human study, it could suggest a potential role for FIR therapy in the treatment 
of cardiovascular disease, where anti-inflammatory and anti-atherosclerotic effects could impact clinical 
outcomes. Conflicting evidence suggests there may be several molecular mechanisms through which FIR acts 
to increase eNOS activity [9]. Bovine aortic endothelial cells irradiated with FIR displayed increased eNOS 
phosphorylation, occurring specifically at the serine 1179 site. Serine 1179 is the principal site at which eNOS 
regulates NO production, and phosphorylation at this site is known to be mediated by various protein kinases 
[41, 42]. Inhibition of protein kinase A and calmodulin-dependent protein kinase-2 (CaMKII) resulted in reduced 
eNOS phosphorylation, suggesting they played an integral role in the mechanism. FIR was also found to increase 
intracellular Ca2+ which modulates CamKII activity. Overall, the experiments suggest that FIR increases 
intracellular Ca2+ causing increased CaMKII activity, which increases eNOS phosphorylation at the serine 1179 
site. Furthermore, it is suggested that FIR may modulate transient receptor potential (TRP) channels, a group of 
cation channels permeable to Ca2+ that are expressed throughout the body including heart and vascular tissue. 
These channels act as cellular sensors and respond to a range of stimuli, including temperature. The discovery 
of these channels is relatively recent, but specific channels have been shown to play a role in maintaining 
endothelium-dependent vasodilation, so they may prove to be important targets of future cardiovascular 
research. In this case the activity of one thermo-sensitive channel, the transient receptor potential vanilloid 
channel, was investigated but its activity did not appear to be altered by FIR irradiation. The increase in CaMKII 
activity and intracellular Ca2+ shown in this study add significant information about how FIR may cause a 
beneficial increase in NO bioavailability, although certain aspects such as the involvement of thermo-sensitive 
TRP channels require further investigation. The evidence that FIR increases eNOS expression and the potential 
clinical benefits of this, seem to warrant further investigation. The significance of the diverse set of potential 
mechanisms which have been identified in the current literature is unclear, and further research is required. 
 
Reduction in oxidative stress and increase in antioxidants 
Oxidative stress occurs when there is an imbalance between anti-oxidant and oxidant production [43]. Reactive 
oxygen species (ROS) play an important role in physiological processes such as cell signaling and more critically 
in pathological ones when they are abnormally produced resulting in oxidative damage. They are involved in the 
pathogenesis of cardiovascular disease, including atherosclerosis and stroke [43]. These highly reactive oxidant 
molecules cause inactivation of NO, leading to endothelial dysfunction and cardiovascular disease [26]. Clinically, 
FIR has been shown to improve vascular endothelial function as measured by flow-mediated dilatation (FMD) 
while reducing surrogate biomarkers reflecting systemic redox status in subjects with cardiovascular conditions. 
Inoue et al. [13] delivered localised FIR irradiation to the legs of patients with congestive heart failure, and 
demonstrated a significant improvement in plasma antioxidant status. This was indicated by increased levels of 
antioxidants; thiol and glutathione peroxidase and reduced levels of 8-hydroxy-2-deoxyguanosine, a marker of 
oxidative DNA damage. Masuda et al. [14] gave FIR sauna therapy to patients with at least one coronary risk 
factor, including hypertension, hyperlipidaemia and diabetes mellitus. In this case, a urinary marker for oxidative 
stress was used, 8-epi-prostaglandin F2α (8-epi-PGF2α). There was a significant reduction in urinary 8-epi-
PGF2α levels in those receiving FIR compared with control subjects. 8-epi-PGF2α opposes NO-mediated 
vasodilation, causing vasoconstriction, so a reduction in this urinary marker suggests FIR may increase vascular 
flow, shear stress and vasodilatation. Indeed, there is further clinical evidence that FIR improves endothelial 
function in patients with coronary risk factors, as measured by FMD [20], the gold-standard non-invasive marker 
of endothelial function [44]. The current body of evidence generally indicates that FIR improves cardiovascular 
function through reduced oxidative stress, though these studies do not address the question of the underlying 
mechanism for this effect, which remains unclear. Studies in animal and cellular models have sought to identify 
potential underlying mechanisms. Four weeks of FIR sauna therapy up-regulated cardiac expression of the 
antioxidant manganese superoxide dismutase as well as heat shock proteins HSP27 and HSP32 in 
cardiomyopathic hamsters. This was mediated by activation of cardiac phospho-p38 mitogenactivated protein 
kinase (pp38MAPK) which is triggered by environmental stresses [3]. HSP32, also known as heme oxygenase-
1 (HO-1) catalyses the rate-limiting step in the degradation of heme to biliverdin, iron and carbon monoxide (CO). 
Biliverdin is subsequently reduced by biliverdin reductase to bilirubin [45]. HO-1 exerts potent anti-oxidant, anti-
inflammatory, antiproliferative and anti-thrombotic effects through the end products bilirubin and CO [46]. In 
keeping with the previous results, a series of studies by Lin et al. have highlighted a beneficial effect of FIR on 
arterio-venous fistula (AVF) for patients with CKD undergoing haemodialysis, through the induction of HO-1 [4, 
7, 47]. Initial evidence from a clinical trial suggested that giving FIR irradiation over the AVF site, during dialysis 
three times weekly, improved vessel patency and flow [7]. A further mechanistic study examined the effects of 
FIR on HUVECs [7] The expression of HO-1 protein and mRNA in HUVECs was increased in a time-dependent 
manner after 40 minutes of FIR irradiation, with the effect peaking between 4–8 hours and returning to baseline 
at 48 hours. This increase was suggested to be mediated by the thermal activation of the Change to ‘nuclear 
factor erythroid 2- related factor 2-anti-oxidant response element (Nrf2/ARE) system.’ Nrf2 is a central regulator 
of oxidative stress which causes transcription of important anti-oxidative target genes, including those encoding 
HO-1 [48]. To confirm the role of Nrf2/ARE in the effect of FIR on HUVECs, a mutation was made to the 
antioxidant response element (ARE), which eliminates Nrf2 activation. This abolished the effect of FIR on 
increasing HO-1 activation, suggesting that the Nrf2-ARE pathway is central to the mechanism by which FIR 
induces HO-1, and this may be responsible for beneficial effects observed in humans. Lin et al. [21] delved further 
into this particular mechanism by examining a naturally occurring genetic variant that affects HO-1 induction in 
patients receiving dialysis. A length polymorphism of the guanosine thymidine repeat in the HO-1 gene results in 
reduced HO-1 production [21]. Genetic testing of patients receiving FIR during haemodialysis identified the length 
polymorphism of either one short (S) [(GT) n ≤ 30] or long (L) [(GT)n ≥ 30] allele. The L/L genotype was associated 
with a profound reduction in HO-1 transcription and a 2.5-fold increased risk of developing AVF malfunction than 
those with other genotypes. The results of this study suggest that in patients with a genetic inability to produce 
HO-1, FIR was unable to exert a beneficial effect. This provides further evidence that HO-1 induction is involved 
in the mechanism of FIR, but as this study was examining changes in the AVF, an abnormal vascular bed, it is 
unclear whether this finding also applies to the physiological cardiovascular system. The exact interplay between 
FIR and oxidative stress remains unclear, and whilst some potential mechanisms for this have been identified, 
including the potential induction of HO-1, there are other aspects of this mechanism which require further study, 
such as the role of Nrf2/ARE. Clinical studies of FIR therapy in populations with high oxidative stress levels such 
as smokers and cardiovascular disease, with a focus on a broad range of measures of redox status as well as 
clinical outcomes could increase the credibility of this mechanism, while further molecular studies are needed to 
fully understand it. 
 
Angiogenesis and endothelial progenitor cells 
It is now understood that the process of angiogenesis, the formation of new blood vessels from endothelial 
progenitor cells (EPCs) which are precursor cells with the ability to differentiate into functional endothelial cells 
[49], occurs in adult humans as well as embryos, and acts to repair damaged blood vessels [50]. Various studies 
in human endothelial cells, peripheral blood and animal models suggest that FIR can mediate angiogenesis. Rau 
et al. [51] irradiated human microvascular endothelial cells derived from the skin for 0, 15 or 30 minutes and 
assessed the cells for angiogenic effects. 15 minutes of FIR doubled the degree of tube formation in the 
endothelial cells, which is an early marker of angiogenesis. The effect of FIR was achieved via the activation of 
extracellular signal regulated kinase (ERK), one of the three mitogen-activated protein kinases involved in 
regulating angiogenesis. Inhibition of ERK significantly attenuated the effect of enhanced angiogenesis. In 
contrast with studies discussed previously, there was no indication that induction of eNOS or the production of 
VEGF were involved. These contrasting results highlight that our understanding of FIR’s interplay with EPCs 
remains limited. However, FIR may promote the formation of new microvasculature, which could provide 
collateral perfusion to ischaemic tissue, for example in peripheral arterial disease (PAD) where atherosclerosis 
leads to chronic ischaemia. This would be in keeping with reports that FIR can improve perfusion to the ischaemic 
limb and reduce symptoms in patients with PAD [49]. PAD is a common manifestation of atherosclerosis and can 
lead to intermittent claudication or critical limb ischaemia, with the latter resulting in limb amputation in severe 
cases. FIR may contribute to repairing atherosclerotic vasculature and improve collateral flow to an ischaemic 
limb. Shinsato et al. [15] found that FIR improved ankle-brachial pressure index and 6-minute walk distance in 
patients with PAD. By analysing samples of peripheral blood mononuclear cells, it was suggested that 
mobilization of CD34+ haematopoietic stem cells may have played a role in the clinical benefits of FIR [15]. 
CD34+ cells are a precursor to EPCs, so an increase in these cells could result in improved intrinsic repair of 
damaged endothelium. The authors also suggested that as FIR increased circulating NO and EPCs, the 
mechanism may be eNOS-dependent. Other studies have highlighted the role of eNOS in mobilising EPCs in 
angiogenesis. 13 eNOS knock out mice showed impaired neovascularization which is related to progenitor cell 
mobilization [52]. Since NO bioavailability is closely related to endothelial function, it can be assumed that in 
patients with PAD there is inadequate repair of the endothelial damage resulting in atherosclerosis and 
ischaemia. Therefore, induction of eNOS and increased NO bioavailability may improve the damaged vessels’ 
inherent ability for selfrepair. This study combines mechanisms relating to NO bioavailability and angiogenesis 
and highlights how both of these mechanisms may result in improved function throughout the diseased 
cardiovascular system. It is worth noting that in contrast, Sobajima [16] unexpectedly found a reduction in CD34+ 
cells at the end of a course of FIR therapy. They studied patients with myocardial ischemia caused by chronic 
occlusion of the coronary arteries. On serial measurements of CD34+ cells throughout the FIR treatments, it was 
found that CD34+ numbers transiently increased during FIR irradiation but decreased towards the end of the 
treatment. Since there was an improvement in endothelial function and myocardial perfusion in patients receiving 
FIR, the reduction in CD34+ was explained by the reduction in ischaemic stimuli during FIR therapy as ischaemia 
is the main trigger for progenitor cells to be recruited from bone marrow to the tissues. There is clearly anuanced 
interaction between FIR and CD34+ cells, and further mechanistic studies are needed to understand the precise 
effects on this cell type. Maintaining adequate perfusion to the peripheries is important in the management of 
patients with diabetes and associated PAD. Administering streptozotocin (STZ) creates a useful mouse-model 
of type 1 diabetes, as the drug results in an inability to produce insulin resulting in uncontrolled hyperglycaemia 
in the absence of exogenous insulin [53]. Huang et al. [54] studied STZ mice with unilateral hindlimb ischaemia, 
giving five weeks of daily wholebody FIR irradiation to the study group. Blood flow to the ischaemic limb, as 
measured by Doppler perfusion imaging, was improved compared to STZ mice that received body heating without 
FIR to control for the hyperthermic effect. It was hypothesised that FIR may affect the activity of EPCs. In mice 
treated with FIR, a greater proportion of EPCs differentiated into endothelial cells. FIR appeared to inhibit 
senescence of EPCs induced by chronic hyperglycaemia, and to reduce oxidative stress as measured by 
hydrogen peroxide production. A novel approach was taken by extracting human EPCs from blood, which were 
treated with FIR irradiation and injected into mice. This improved collateral flow recovery in the ischaemic limb. 
Although only limited comparisons can be drawn between an animal model and human diabetic patients, this 
study suggests the potential of FIR to improve collateral perfusion to the ischaemic limb by increasing EPC 
activity could be worthy of further investigation. Increasing the reparative activity of EPCs could also be beneficial 
in ischaemic disease at other sites in the cardiovascular system. Further investigation of how FIR affects human 
EPCs is fundamental in targeting these cells therapeutically. In one study, normal human volunteers gave 
peripheral venous blood samples and EPCs were isolated from total mononuclear cells [10]. The cells were 
treated with glucose for four days to simulate the effects of hyperglycaemia in diabetes. EPCs were then treated 
with FIR for 30 minutes and microarrays were done to assess for expression of various genes. FIR significantly 
up-regulated eNOS transcripts, in keeping with mechanisms previously discussed. More interestingly, FIR 
significantly up-regulated genes coding for MAPKs, Janus kinase/signal transducer and activator of transcription 
(JAK/STAT) and prostaglandin signaling pathways and down-regulated genes involved with cardiac fibrosis. The 
functional significance of this is not entirely clear, as activation of the MAPK/ERK and JAK/STAT signaling 
pathways has pro-inflamatory actions, which may not be beneficial to cardiovascular health [55]. FIR increased 
gene expression for prostaglandin signalling pathways, which could lead to increased production of prostacyclins, 
resulting in vasodilation and improved endothelial function [56]. Another study [11] exploring the interaction 
between hyperglycaemia-induced endothelial dysfunction and FIR, suggested that FIR may exert a beneficial 
effect by suppressing microRNA-134. Micro-RNAs are non-coding RNA molecules involved in post-
transcriptional gene regulation [57]. Endothelial colony-forming cells (ECFCs), a subtype of EPCs with reparative 
angiogenic capabilities were collected from normal or diabetic human blood and isolated from HUVECs. 
MicroRNA-134 was increased in hyperglycaemic states and resulted in impaired angiogenic activity in ECFCs. 
When dysfunctional ECFCs were treated with FIR, then re-injected into a mouse ischaemic hindlimb, perfusion 
improved significantly, with a reduced effect when microRNA-134 was overexpressed. This represents another 
potential mechanism for the effects of FIR irradiation on angiogenic activity in endothelial cells, which could be 
significant if replicated in further studies. Clinical research is required to establish whether FIR has a beneficial 
effect on EPCs in humans and whether this is translated into an improvement in clinical outcomes in 
cardiovascular disease, where an improved ability to self-repair damaged blood vessels could have a significant 
impact. 
 
Inflammation and thrombogenesis  
Inflammation is inherently linked to the pathogenesis of cardiovascular disease [58]. Myocardial infarction, 
peripheral vascular disease and ischaemic stroke all stem from risk factors such as smoking and hypertension, 
which trigger endothelial dysfunction and lead to atherosclerosis. An anti-inflammatory effect is supported by 
studies discussed previously that suggest FIR upregulates HO-1, an enzyme which in addition to anti-oxidant 
effects, also exerts anti-inflammatory actions through the production of CO and bilirubin [7]. Lin and colleagues 
showed that FIR induced HO-1 enzyme activity in HUVECs, which appeared to block the expression of adhesion 
molecules mediated by the inflammatory cytokine tumour necrosis factor-alpha [7]. These adhesion molecules 
promote atherosclerosis by attracting macrophages to the endothelium, resulting in the formation of fatty streaks, 
which progress to atherosclerotic plaque. Another key pathological process in atherosclerosis and thrombosis is 
platelet aggregation. Investigators in Taiwan [59] showed that FIR reduced the expression of 19 genes related 
to platelet aggregation in human umbilical vein endothelial cells through reduced expression of thromboxane A2 
receptor. Although platelet adhesion and aggregation have an important role in thrombogenesis, measuring 
platelet function has not been shown to accurately predict the onset of ischaemic heart disease (IHD), so the 
potential clinical benefits of this may be limited. 
 
Conclusion 
This review shows that at present, there is some evidence that FIR could provide a beneficial effect to the 
cardiovascular system through increases in eNOS activity, a reduction in oxidative stress through the induction 
of HO-1, activation of endothelial progenitor cells to repair damaged vasculature and an anti-inflammatory effect. 
The involvement of these mechanisms appears to be independent of a direct heating effect of FIR irradiation. 
Within each of these categories, a number of potential mechanisms have been identified, though many are only 
evidenced by a single study and their significance is unclear. In some cases, the potential mechanisms identified 
may form part of a wider mechanism that is not fully understood. Human studies to date have focused 
predominantly on large vessel measures of endothelial function such as FMD, but improved microvascular flow 
has been shown in animal models of ischaemia and microvascular angiogenesis has been studied in cellular 
models. In order to establish the mechanisms of FIR on the cardiovascular system, more studies are required, 
as there are few robust studies and little consensus on which molecular mechanisms are most significant, as few 
have been replicated. Further research in humans is particularly needed, as few of the potential mechanisms 
found in animals have been translated into humans thus far. A clearer understanding of the mechanisms of FIR 
in humans is fundamental to unlocking its potential clinical benefits. Once a better understanding of the molecular 
mechanisms is achieved, the next step is to investigate the effects of FIR in patients with conditions such as 
PAD, diabetes and hypertension, for whom it could represent a novel, non-invasive therapy to augment current 
pharmacological and surgical approaches. 
 
 
Figure 2 Summary of main mechanisms. (1) FIR increases endothelial progenitor cell (EPC) activity (precursors that differentiate 
into endothelial cells). (2) Upregulation of Heme oxygenase-1 (HO-1) which cleaves heme into bilirubin and CO, which both act as 
potent antioxidants. (3) FIR causes an increase in laminar shear stress through increasing peripheral blood flow which stimulates 
the expression of endothelial NO synthase (eNOS). (4) FIR directly upregulates eNOS and increases production of nitric oxide (NO) 
and improves endothelial function. (5) FIR might upregulate nuclear erythroid-2 like factor-2 (Nrf2) expression, a transcription 
factor that regulates antioxidant expression through binding to the endogenous antioxidant response elements (AREs) in the 
nucleus. 
 
Table 1 Human studies examining potential mechanisms for the effects of FIR in cardiovascular disease. 
Author, year  Condition  FIR delivery  Beneficial clinical or neurohumoral 
effect 
Potential mechanism 
Inoue 2012 [13]  Chronic heart failure Localised FIR device Improves hemodynamics endothelial 
function and oxidative stress 
Increased antioxidants 
thiol and GPx and 
reduced oxidative stress 
(8OHdG) 
     
Masuda 2004 
[14] 
CV risk factors Sauna Reduced systolic BP Reduced oxidative 
stress (8-epi-PGF2α) 
Shinsato 2010 
[15] 
PAD Sauna Improved ABPI and walk distance Increased number and 
mobilisation of EPCs 
Sobajima 2013 
[16] 
Cardiac ischaemia Sauna Increased myocardial perfusion and 
endothelial function 
 CD34+ cells (no 
significant change) 
Ohori 2012 [17] Chronic heart failure Sauna Increased LVEF, improved FMD, 
Reduced plasma adrenaline, BNP 
Increased CD34+ cells 
Fujita 2011 [3] Chronic heart failure Sauna Reduced plasma BNP, increased 
LVEF 
Reduced oxidative 
stress (hydroperoxide)-
Increased NO 
production 
Miyata 2008 
[18] 
Chronic heart failure Sauna Reduced cardiothoracic ratio, 
plasma BNP Increased LVEF  
KIhara 2002 
[19] 
Chronic heart failure Sauna Reduced symptoms of CHF, 
BNP, systolic BP Improved FMD  
Imamura 2001 
[20] 
CV risk factors Sauna Reduced BP, improved FMD  
Lin 2013 [21] CKD patients on 
dialysis 
Localised FIR device Improved AVF access flow and 
patency in patients 
HO-1 (FIR had lesser 
effect in patients with 
genotype causing 
reduced production of 
HO-1) 
Kuwahata 2011 
[22] 
Chronic heart failure Sauna Increased LVEF, reduced plasma 
noradrenaline 
Reduced autonomic 
nervous system activity 
8-epi-PFG2α: 8-epi-prostaglandin F2 alpha; 8OHdG: 8-hydroxy-2’ – deoxyguanosine; BNP: brain natriuretic peptide; BP: blood pressure; CD34+ cell: 
haematopoietic progenitor cell antigen 34 cell; CHF: chronic heart failure; CV: cardiovascular; EPC: endothelial progenitor cells; FMD: flow-mediated 
dilation; GPx: Glutathione peroxidase; HO-1: heme oxygenase-1; LVEF: left ventricular ejection fraction; PAD: peripheral arterial disease. 
 
Table 2 In-vivo studies with potential mechanisms of FIR. 
Author, 
year 
Model Potential mechanism and or effect 
Fujita 2011 
[3] Cardiomyopathic hamsters 
Increased LV contractility, reduced oxidative stress (4-HNE), Up-regulation of 
Mn-SOD, HSPs 27 and 32 
Akasaki 
2006 [28] Mouse hindlimb ischaemia Increased perfusion to hindlimb via induction of eNOS 
Ikeda 2001 
[29] Healthy hamsters Induction of eNOS, reduced BP 
Ikeda 2005 
[30] Cardiomyopathic hamsters Increased eNOS mRNA 
Ihori 2016 
[31] Hypertensive rats Induction of eNOS 
Sobajima 
2011 [32] Myocardial ischemic rats 
Inhibition of ventricular remodelling and increased vascularisation via 
upregulation of eNOS and VEGF 
Miyauchi 
2012 (33) 
Mouse hindlimb ischaemia Angiogenesis through upregulation of HSP90 which activates Akt/eNOS 
pathway 
Huang 
2012 (54) 
Hyperglycaemic mice with hindlimb ischaemia Increased angiogenesis through increased endothelial progenitor cell activity 
4-HNE: 4-hydroxynonenal; BP: blood pressure; eNOS: endothelial nitric oxide synthase; HSP: heat shock protein; LV: left ventricle; Mn-SOD: 
manganese-dependent superoxide dismutase; VEGF: vascular endothelial growth factor 
Table 3 In-vitro studies with potential mechanisms of FIR. 
Author, year Model Potential mechanism and or effect 
Lin 2008 [7] Human umbilical vein endothelial cells Reduced oxidative stress, Induction of HO-1 
Hsu 2012 [8] Human umbilical vein endothelial cells Increased NO production through: Increased phosphorylation of PKB/ 
Akt through induction of PI3K nuclear translocation of PLZF 
Park 2013 [9] Bovine aortic endothelial cells Increased NO production through: Increased CaMKII activity and 
increased eNOS phosphorylation at serine 1179 site 
Rau 2011 
[51] Human microvascular endothelial cells Increased angiogenesis through ERK and p38 activation 
Lin 2015 [10] Endothelial progenitor cells from healthy 
human blood Activation of JAK/STAT signalling, activation of prostaglandin signalling 
Wang 2016 
[11] 
Endothelial progenitor cells from healthy/ 
diabetic human blood 
Increased endothelial progenitor cell activity through suppression of 
MicroRNA-134 
ERK: extracellular receptor kinase; CaMKII: calmodulin-dependent protein kinase II; HO-1: heme oxygenase-1; JAK/STAT: janus kinase/signal 
transducer and activator of transcription; PI3K: phosphoinositide 3 kinase; PKB/AKT: protein kinase B/Akt; PLZF: promyelocytic. 
 
 
References 
1. Vatansever F, Hamblin MR. Far infrared radiation (FIR): its biological effects and medical applications. Photonics Lasers 
Med. 2012 Nov 1;4:255–66. 
2. Sobajima M, Nozawa T, Fukui Y, Ihori H, Ohori T, Fujii N, et al. Waon Therapy Improves Quality of Life as Well as 
Cardiac Function and Exercise Capacity in Patients With Chronic Heart Failure. Int Heart J. 2015;56(2):203–8. 
3. Fujita S, Ikeda Y, Miyata M, Shinsato T, Kubozono T, Kuwahata S, et al. Effect of Waon therapy on oxidative stress in 
chronic heart failure. Circ J. 2011;75(2):348–56. 
4. Lin C-C, Chang C-F, Lai M-Y, Chen T-W, Lee P-C, Yang W-C. Farinfrared therapy: a novel treatment to improve access 
blood flow and unassisted patency of arteriovenous fistula in hemodialysis patients. J Am Soc Nephrol. 2007;18(3):985–
92. 
5. Toyokawa H, Matsui Y, Uhara J, Tsuchiya H, Teshima S, Nakanishi H, et al. Promotive effects of far-infrared ray on full-
thickness skin wound healing in rats. Exp Biol Med (Maywood). SAGE Publications; 2003 Jun 1;228(6):724–9. 
6. Vita JA, Keaney JF. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002 Aug 6;106(6):640–2. 
7. Lin C-C, Liu X-M, Peyton K, Wang H, Yang W-C, Lin S-J, et al. Far infrared therapy inhibits vascular endothelial 
inflammation via the induction of heme oxygenase-1. Arterioscler Thromb Vasc Biol. 2008;28(4):739–45. 
8. Hsu Y-H, Chen Y-C, Chen T-H, Sue Y-M, Cheng T-H, Chen J-R, et al. Far-infrared therapy induces the nuclear 
translocation of PLZF which inhibits VEGF-induced proliferation in human umbilical vein endothelial cells. PLoS One. 
2012;7(1):e30674. 
9. Park J-H, Lee S, Cho D-H, Park YM, Kang D-H, Jo I. Far-infrared radiation acutely increases nitric oxide production by 
increasing Ca2+ mobilization and Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation of endothelial 
nitric oxide synthase at serine 1179. Biochem Biophys Res Commun. 2013 Jul;436(4):601–6. 
10. Lin T-C, Lin C-S, Tsai T-N, Cheng S-M, Lin W-S, Cheng C-C, et al. Stimulatory Influences of Far Infrared Therapy on the 
Transcriptome and Genetic Networks of Endothelial Progenitor Cells Receiving High Glucose Treatment. Acta Cardiol 
Sin. Taiwan Society of Cardiology; 2015 Sep;31(5):414–28. 
11. Wang HW, Su SH, Wang YL, Chang ST, Liao KH, Lo HH, et al. MicroRNA-134 contributes to glucose-induced endothelial 
cell dysfunction and this effect can be reversed by farinfrared irradiation. PLoS One. Public Library of Science; 2016 Jan 
1;11(1). 
12. Lin C-C, Chung M-Y, Yang W-C, Lin S-J, Lee P-C. Length polymorphisms of heme oxygenase-1 determine the effect of 
farinfrared therapy on the function of arteriovenous fistula in hemodialysis patients: a novel physicogenomic study. 
Nephrol Dial Transplant. 2013 May 1;28(5):1284–93. 
13. Inoue S, Takemoto M, Chishaki A, Ide T, Nishizaka M, Miyazono M, et al. Leg heating using far infra-red radiation in 
patients with chronic heart failure acutely improves the hemodynamics, vascular endothelial function, and oxidative stress. 
Intern Med. 2012;51(17):2263–70. 
14. Masuda A, Miyata M, Kihara T, Minagoe S, Tei C. Repeated sauna therapy reduces urinary 8-Epi-Prostaglandin F2α. Jpn 
Heart J. 2004 Apr 14;45(2):297–303. 
15. Shinsato T, Miyata M, Kubozono T, Ikeda Y, Fujita S, Kuwahata S, et al. Waon therapy mobilizes CD34+ cells and 
improves peripheral arterial disease. J Cardiol. Japanese College of Cardiology; 2010;56(3):361–6. 
16. Sobajima M, Nozawa T, Ihori H, Shida T, Ohori T, Suzuki T, et al. Repeated sauna therapy improves myocardial perfusion 
in patients with chronically occluded coronary arteryrelated ischemia. Int J Cardiol. 2013 Jul;167(1):237–43. 
17. Ohori T, Nozawa T, Ihori H, Shida T, Sobajima M, Matsuki A, et al. Effect of Repeated Sauna Treatment on Exercise 
Tolerance and Endothelial Function in Patients With Chronic Heart Failure. Am J Cardiol. 2012 Jan;109(1):100–4. 
18. Miyata M, Kihara T, Kubozono T, Ikeda Y, Shinsato T, Izumi T, et al. Beneficial effects of Waon therapy on patients with 
chronic heart failure: Results of a prospective multicenter study. J Cardiol. 2008 Oct;52(2):79–85. 
19. Kihara T, Biro S, Imamura M, Yoshifuku S, Takasaki K, Ikeda Y, et al. Repeated sauna treatment improves vascular 
endothelial and cardiac function in patients with chronic heart failure. J Am Coll Cardiol. 2002 Mar;39(5):754–9. 
20. Imamura M, Biro S, Kihara T, Yoshifuku S, Takasaki K, Otsuji Y, et al. Repeated thermal therapy improves impaired 
vascular endothelial function in patients with coronary risk factors. J Am Coll Cardiol. 2001;38(4):1083–8. 
21. Lin C-C, Chung M-Y, Yang W-C, Lin S-J, Lee P-C. Length polymorphisms of heme oxygenase-1 determine the effect of 
farinfrared therapy on the function of arteriovenous fistula in hemodialysis patients: a novel physicogenomic study. 
Nephrol Dial Transplant. 2013 May 1;28(5):1284–93. 
22. Kuwahata S, Miyata M, Fujita S, Kubozono T, Shinsato T, Ikeda Y, et al. Improvement of autonomic nervous activity by 
Waon therapy in patients with chronic heart failure. J Cardiol. 2011 Jan;57(1):100–6. 
23. Mark PB. Strategies to manage cardiovascular risk in chronic kidney disease. Nephrol Dial Transplant. Oxford University 
Press; 2018 Jan;33(1):23–5. 
24. van der Sande C, Kwa M, van Nues R, van Heerikhuizen H, RauA H, Planta R. The pivotal role of nitric oxide for vascular 
health. J Mol Biol. 1992. p. 223(4). 
25. Ziegler T, Silacci P, Harrison VJ, Hayoz D. Nitric Oxide Synthase Expression in Endothelial Cells Exposed to Mechanical 
Forces. Hypertension. 1998 Aug;32(2):351–6. 
26. Förstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006 
Apr 4;113(13):1708–14. 
27. Tei C, Horikiri Y, Park JC, Jeong JW, Chang KS, Toyama Y, et al. Acute hemodynamic improvement by thermal 
vasodilation in congestive heart failure. Circulation. 1995 May 15;91(10): 2582–90. 
28. Akasaki Y, Miyata M, Eto H, Shirasawa T, Hamada N, Ikeda Y, et al. Repeated thermal therapy up-regulates endothelial 
nitric oxide synthase and augments angiogenesis in a mouse model of hindlimb ischemia. Circ J.;2006 Apr;70(4):463–70. 
29. Ikeda Y, Biro S, Kamogawa Y, Yoshifuku S, Eto H, Orihara K, et al. Repeated thermal therapy upregulates arterial 
endothelial nitric oxide synthase expression in Syrian golden hamsters. Jpn Circ J. 2001 May;65(5):434–8. 
30. Ikeda Y, Biro S, Kamogawa Y, Yoshifuku S, Eto H, Orihara K, et al. Repeated sauna therapy increases arterial endothelial 
nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. Circ J. 2005 Jun;69(6):722–9. 
31. Ihori H, Nozawa T, Sobajima M, Shida T, Fukui Y, Fujii N, et al. Waon therapy attenuates cardiac hypertrophy and 
promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin. Heart Vessels. 2016 Aug 
19;31(8): 1361–9. 
32. Sobajima M, Nozawa T, Shida T, Ohori T, Suzuki T, Matsuki A, et al. Repeated sauna therapy attenuates ventricular 
remodelling after myocardial infarction in rats by increasing coronary vascularity of noninfarcted myocardium. AJP Hear 
Circ Physiol. 2011 Aug 1;301(2):H548–54. 
33. Miyauchi T, Miyata M, Ikeda Y, Akasaki Y, Hamada N, Shirasawa T, et al. Waon therapy upregulates Hsp90 and leads to 
angiogenesis through the Akt-endothelial nitric oxide synthase pathway in mouse hindlimb ischemia. Circ J. 
2012;76(7):1712–21. 
34. Zuo D, Subjeck J, Wang X-Y. Unfolding the role of large heat shock proteins: new insights and therapeutic implications. 
Front Immunol. 2016 Jan;7:75. rendertype=abstract 
35. Kalmar B, Greensmith L. Induction of heat shock proteins for protection against oxidative stress. Adv Drug Deliv Rev. 
Elsevier B. V.; 2009;61(4):310–8. 
36. Brouet A, Sonveaux P, Dessy C, Balligand JL, Feron O. Hsp90 ensures the transition from the early Ca2+-dependent to 
the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth 
factorexposed endothelial cells. J Biol Chem. 2001 Aug 31;276(35): 32663–9. 
37. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci. 2001;114(8). 
38. Luo Z, Fujio Y, Kureishi Y, Radu DR, Daumerie G, Fulton D, et al. Acute modulation of endothelial Akt/PKB activity alters 
nitric oxide–dependent vasomotor activity in vivo. J Clin Invest. 2000;106(4):493–9. 
39. Fernandez-Hernando C, Ackah E, Yu J, Suarez Y, Murata T, Iwakiri Y, et al. Loss of Akt1 leads to severe atherosclerosis 
and occlusive coronary artery disease. Cell Metab. NIH Public Access; 2007 Dec;6(6):446–57. 
40. Mukai Y, Rikitake Y, Shiojima I, Wolfrum S, Satoh M, Takeshita K, et al. Decreased vascular lesion formation in mice with 
inducible endothelial-specifi c expression of protein kinase Akt. J Clin Invest. 2006 Jan 19;116(2):334–43. 
41. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide 
production by the protein kinase Akt. Nature. NIH Public Access; 1999 Jun 10;399(6736):597–601. 
42. Bae SW, Kim HS, Cha YN, Park YS, Jo SA, Jo I. Rapid increase in endothelial nitric oxide production by bradykinin is 
mediated by protein kinase A signaling pathway. Biochem Biophys Res Commun. 2003 Jul 11;306(4):981–7. 
43. Heistad DD, Wakisaka Y, Miller J, Chu Y, Pena-Silva R. Novel aspects of oxidative stress in cardiovascular diseases. Circ 
J. 2009;73(2):201–7. 
44. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, et al. The assessment of endothelial 
function: from research into clinical practice. Circulation. 2012;126(6): 753–67. 
45. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008 Mar 
1;60(1):79–127. 
46. Ryter SW, Alam J, Choi AMK. Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications. 
Physiol Rev. 2006;86:583–650. 
47. Lin C-C, Yang W-C, Chen M-C, Liu W-S, Yang C-Y, Lee P-C. Effect of far infrared therapy on arteriovenous fistula 
maturation: an open-label randomized controlled trial. Am J Kidney Dis. National Kidney Foundation, Inc.; 
2013;62(2):304–11. 
48. Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who’s listening? Antioxid Redox Signal. 
2010 Dec 1;13(11):1649–63. 
49. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for 
angiogenesis. Science. 1997 Feb 14;275(5302):964–7. 
50. Freedman SB, Isner JM. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol. 2001 
Mar;33(3): 379–93. 
51. Rau C-S, Yang JC-S, Jeng S-F, Chen Y-C, Lin C-J, Wu C-J, et al. Far-Infrared Radiation Promotes Angiogenesis in 
Human Microvascular Endothelial Cells via Extracellular Signal-Regulated Kinase Activation. Photochem Photobiol. 
Blackwell Publishing Ltd; 2011 Mar;87(2):441–6. 
52. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric 
oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9(11):1370–6. 
53. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008 Feb 18;51(2):216–26. 
54. Huang P-H, Chen J-W, Lin C-P, Chen Y-H, Wang C-H, Leu H-B, et al. Far infra-red therapy promotes ischemia-induced 
angiogenesis in diabetic mice and restores high glucosesuppressed endothelial progenitor cell functions. Cardiovasc 
Diabetol. 2012;11(1):99. 
55. Grote K, Luchtefeld M, Schieffer B. JANUS under stress-role of JAK/STAT signaling pathway in vascular diseases. Vascul 
Pharmacol. 2005 Nov;43(5):357–63. 
56. Park K-H, Park WJ. Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic 
Approaches. J Korean Med Sci. Korean Academy of Medical Sciences; 2015 Sep;30(9):1213–25. 
57. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004 Jan 23;116(2):281–97. 
58. Ross R. Inflammation or Atherogenesis. N Engl J Med. 1999; 340(2):115–26. 
59. Chen W, Hwang DW, Hwang SJ. Far Infrared radiation inhibits throboxane A2 receptor gene expression in human 
umbilical vein endothelial cells. Neph Dial Transplant. 2015 May;30 (Supplement 3):iii572. 
